Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro

A major challenge in coronavirus vaccination and treatment is to counteract rapid viral evolution and mutations. Here we demonstrate that CRISPR-Cas13d offers a broad-spectrum antiviral (BSA) to inhibit many SARS-CoV-2 variants and diverse human coronavirus strains with >99% reduction of the vira...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Leiping, Liu, Yanxia, Nguyenla, Xammy Huu, Abbott, Timothy R., Han, Mengting, Zhu, Yanyu, Chemparathy, Augustine, Lin, Xueqiu, Chen, Xinyi, Wang, Haifeng, Rane, Draven A., Spatz, Jordan M., Jain, Saket, Rustagi, Arjun, Pinsky, Benjamin, Zepeda, Adrianna E., Kadina, Anastasia P., Walker, John A., Holden, Kevin, Temperton, Nigel, Cochran, Jennifer R., Barron, Annelise E., Connolly, Michael D., Blish, Catherine A., Lewis, David B., Stanley, Sarah A., La Russa, Marie F., Qi, Lei S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119983/
https://www.ncbi.nlm.nih.gov/pubmed/35589813
http://dx.doi.org/10.1038/s41467-022-30546-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119983/
https://www.ncbi.nlm.nih.gov/pubmed/35589813
http://dx.doi.org/10.1038/s41467-022-30546-7

Ejemplares similares